Maze Therapeutics, Inc. (MAZE) AI Stock Price Forecast & Investment Analysis
Latest Analysis Date: August 22, 2025
Maze Therapeutics, Inc. (MAZE) - Comprehensive Stock Analysis & Investment Research
Company Overview & Business Profile
Maze Therapeutics, Inc. (Stock Symbol: MAZE)
is a leading company in the Life Sciences sector
, specifically operating within the Biological Products, (No Diagnostic Substances) industry.
.
The company has established itself as
an emerging investment opportunity with substantial growth potential.
Financial Performance & Key Metrics Analysis
Market Capitalization: $592 million - Classified as a
small-cap investment offering high growth potential.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Maze Therapeutics, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
Maze Therapeutics, Inc. strategically competes in the highly dynamic
Biological Products, (No Diagnostic Substances) marketplace,
representing an emerging small-cap investment with substantial growth potential and market disruption capabilities
.
.
Maze Therapeutics, Inc. Stock Price Chart and Technical Analysis
Loading chart data...
Loading Maze Therapeutics, Inc. interactive price chart and technical analysis...
Deep dive into Maze Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.
Understanding Valuation Metrics
What these metrics mean: Valuation metrics help determine if Maze Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.
How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.
For Maze Therapeutics, Inc.:
P/B Ratio2.26x
Market Cap$592M
EPS$-1.15
Book Value/Share$5.98
Understanding Profitability Metrics
What these metrics mean: These ratios measure how efficiently Maze Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.
How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.
For Maze Therapeutics, Inc.:
Understanding Financial Health Metrics
What these metrics mean: These ratios assess Maze Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.
How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.
For Maze Therapeutics, Inc.:
Understanding Cash Flow Metrics
What these metrics mean: Cash flow metrics reveal Maze Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.
How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.
For Maze Therapeutics, Inc.:
Understanding Operational Efficiency Metrics
What these metrics mean: These ratios measure how effectively Maze Therapeutics, Inc. uses its assets and manages working capital.
How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.
For Maze Therapeutics, Inc.:
Understanding Financial Statement Data
What these metrics mean: Key figures from Maze Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.
How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.
For Maze Therapeutics, Inc.:
Income Statement ($ Millions)
Operating Income$-141M
Net Income$-131M
R&D Expense$110M
Balance Sheet Highlights ($ Millions)
Dividend & Shareholder Information
Shares Outstanding44M
Growth Metrics (YoY)
EPS Growth-34.1%
Maze Therapeutics, Inc. (MAZE) Fundamental Analysis & Insider Trading Data
(Quarterly Financial Reports)
Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Maze Therapeutics, Inc. stock analysis.
Loading fundamental data...
Loading Maze Therapeutics, Inc. comprehensive fundamental analysis and insider trading data...
Latest Maze Therapeutics, Inc. Stock News & Market Analysis
Breaking news, analyst reports, and market updates affecting Maze Therapeutics, Inc. (MAZE) stock price and investment outlook.
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients ...
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease ...
Maze Therapeutics, Inc., a biopharmaceutical company focused on developing precision medicines for renal, metabolic, and cardiovascular diseases, announced that CEO Jason Coloma, Ph.D., will ...
--Maze Therapeutics, Inc., a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today announced ...
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop ...
"This has no therapeutic boundaries," Homcy said. "We can have an impact across a variety of diseases." Maze lined up $191 million led by Third Rock Ventures and ARCH Venture Partners.
Maze Therapeutics Inc. has raised about $400 million in venture capital since its 2019 launch on the promise of a platform for using genetic insights to develop new drugs.
SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for ...
Maze Therapeutics, Inc. Competitors & Peer Analysis - Life Sciences Sector
Comparative analysis of Maze Therapeutics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.
Frequently Asked Questions - Maze Therapeutics, Inc. Stock Forecast
How accurate are Maze Therapeutics, Inc. stock predictions?
Our AI model demonstrates 48% historical accuracy for MAZE predictions, based on advanced machine learning algorithms trained on over 10 years of market data.
What factors influence Maze Therapeutics, Inc. stock price forecasts?
Is Maze Therapeutics, Inc. a good investment in 2025?
Based on our AI analysis, Maze Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.
How often are Maze Therapeutics, Inc. forecasts updated?
Maze Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.
Want More Advanced Maze Therapeutics, Inc. Analysis?
Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Maze Therapeutics, Inc. stock.
